|
C6ORF162 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
5.94430060729678E-11 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
6.960300E-02 |
| Stage1-vs-Stage3 |
1.820000E-02 |
| Stage1-vs-Stage4 |
3.190500E-04 |
| Stage2-vs-Stage3 |
1.324040E-03 |
| Stage2-vs-Stage4 |
7.7991000000055E-05 |
| Stage3-vs-Stage4 |
8.558300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.6631000021583E-08 |
| Normal-vs-Asian |
1.62536650805123E-12 |
| Caucasian-vs-AfricanAmerican |
2.188800E-01 |
| Caucasian-vs-Asian |
9.110300E-02 |
| AfricanAmerican-vs-Asian |
6.909800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
6.740800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
4.78609999965407E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.738400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.626000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.650600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.778000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.611200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.936000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.009610E-02 |
| Classical-VS-Follicular |
1.39239999996654E-06 |
| Classical-VS-Other |
5.823800E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
1.31149999749169E-08 |
| Tall-VS-Other |
5.253600E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.674800E-01 |
| Follicular-VS-Normal |
1.509803393418E-11 |
| Other-VS-Normal |
5.87209999999283E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62436730732907E-12 |
| N0-vs-N1 |
4.713700E-02 |
|
|
